ReviewProgress in cardiovascular diseases

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.

Vinay Garg et al.PubMed ↗Publisher ↗

No numbers read from the abstract.